Opsonin Pharma Limited
Opsonin Pharma Limited, a prominent player in the pharmaceutical industry, is headquartered in Bangladesh (BD) and operates extensively across South Asia. Founded in 1990, the company has established itself as a leader in the development and manufacturing of high-quality generic medicines, particularly in the fields of anti-infectives, cardiovascular, and diabetes care. With a commitment to innovation, Opsonin Pharma has achieved significant milestones, including the introduction of several unique formulations that cater to the evolving healthcare needs of the region. The company’s robust portfolio of products is distinguished by its adherence to stringent quality standards and a focus on affordability, making essential medications accessible to a broader population. Opsonin Pharma's dedication to excellence has solidified its market position, earning recognition for its contributions to public health and pharmaceutical advancements in Bangladesh and beyond.
DitchCarbon Score
How does Opsonin Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Opsonin Pharma Limited's score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Opsonin Pharma Limited's reported carbon emissions
Opsonin Pharma Limited, headquartered in Bangladesh (BD), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Opsonin Pharma may not have established formal climate commitments or initiatives aimed at reducing its carbon footprint. In the context of the pharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate action. While Opsonin Pharma has not yet disclosed its emissions or commitments, it is essential for organisations in this sector to consider implementing strategies that align with global climate goals, such as those set by the Science Based Targets initiative (SBTi) or other industry standards. As the company moves forward, establishing clear climate commitments and reporting on emissions could enhance its sustainability profile and contribute positively to the broader efforts in combating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Opsonin Pharma Limited is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
